Shiseido Future Solutions LX Triple Points Bonus contains SPF 50+ (octinoxate 4.9%
Recall D-0218-2018, part of FDA recall event 78791. See Shiseido America's company page.
SHISEIDO AMERICA INC. started this Class II drug recall on Dec 14, 2017 (voluntary: firm initiated); FDA lists it as terminated, terminated Jun 24, 2021.
- Classification: Class II
- Started: Dec 14, 2017
- Status: Terminated
- Products in this event: 5
GMP Deviations: manufacturing of API material did not meet GMP and quality requirements.
- Product
- Shiseido Future Solutions LX Triple Points Bonus contains SPF 50+ (octinoxate 4.9%, octocrylebe 3.0%, oxybenzone 1.0% and zinc oxide 15.4%), packaged in 15 mL tubes, Shiseido Americas Corporation Dist. New York, NY 10022, NDC 58411-256-60
- Quantity
- N/A
- Lots and codes
- SKU#: 95284
- Distribution
- Product was distributed nationwide.
- Recalling firm
- SHISEIDO AMERICA INC., East Windsor, NJ, United States
- How the firm notified
- Letter
- FDA classified
- Jan 12, 2018
- Shiseido Future Solution LX Universal Defense SPF 50+ (octinoxate 4.9%, octocrylebe 3.0%, oxybenzone 1.0% and zinc…D-0215-2018 · Class II · Dec 14, 2017 · Terminated
- Shiseido Future Solution LX Discovery Set contains SPF 50+ (octinoxate 4.9%, octocrylebe 3.0%, oxybenzone 1.0% and zinc…D-0216-2018 · Class II · Dec 14, 2017 · Terminated
- bareMinerals Broad Spectrum SPF 50 Daily Prep Lotion (zinc oxide 23.8%, titanium dioxide 4.1%), 40 mL/1.35 fl. oz.…D-0214-2018 · Class II · Dec 14, 2017 · Terminated
- Shiseido Future Solution LX Luxurious Eye & Lip Collection contains SPF 50+ (octinoxate 4.9%, octocrylebe 3.0%,…D-0217-2018 · Class II · Dec 14, 2017 · Terminated
FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports